Valuation dashboard for Humacyte, Inc. (HUMA) with P/E N/A, P/B 4.30, EV/EBITDA -1.10 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Analysis Summary
Humacyte, Inc. reported revenue of $2.0M in the most recent fiscal year, growing at a 5-year CAGR of 6.4%.
Trailing-twelve-month margins: gross margin -6.7%, operating margin -52.4%, net margin -45.6%.
At the current price of $0.57, HUMA has negative trailing earnings (P/E not meaningful) and an ROE of -9.38%. Market capitalisation stands at $96M.
Balance sheet quality for HUMA: current ratio of 3.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.30 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HUMA | Humacyte, Inc. | $96M | 4.30 | -9.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.57 |
| Market Cap | $96M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -938.20% |
| Return on Invested Capital | -89.17% |
| Return on Assets | -70.05% |
| Gross Margin | -666.81% |
| Operating Margin | -5240.78% |
| Net Margin | -4560.82% |
Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT
Explore sector: Healthcare · Biotechnology
More sections of HUMA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks